Persistent bloating, pelvic or abdominal pain, feeling full quickly and needing to urinate more often can have many causes. NICE includes a CA 125 blood test in the investigation pathway for people with symptoms that could be associated with ovarian cancer. The word “cancer marker” can sound definitive, but CA 125 cannot confirm or exclude cancer by itself.
CA 125 is a protein that can rise when tissues lining the abdomen or pelvis are irritated. Ovarian cancer is one possible reason, but periods, endometriosis, fibroids, pregnancy, pelvic infection, liver disease and other conditions can also raise it. Some ovarian cancers do not produce a raised level, particularly at an earlier stage.
That combination means CA 125 is not recommended as a general reassurance test for someone without symptoms or risk factors. Its value is in a defined pathway: symptoms and clinical history first, then the blood result, and ultrasound or further assessment when indicated.
What this test measures
The test measures cancer antigen 125, also known as CA 125, in blood. The protein is associated with cells derived from the coelomic lining, including the lining of the abdomen and reproductive organs. Irritation or inflammation of these tissues can increase the amount detected.
The laboratory reports a concentration and reference information. NICE uses a threshold within its symptomatic assessment pathway to guide whether ultrasound should be arranged, but age, menopausal status and the full clinical picture matter. A result is not a tissue diagnosis and does not show where a rise comes from.
CA 125 does not replace pelvic examination, ultrasound or urgent referral where symptoms warrant them. It also does not replace NHS cervical screening, which checks the cervix, or breast screening. These programmes address different tissues and risks.
When testing may be useful
Speak with your GP when bloating, early fullness, pelvic or abdominal pain, or urinary urgency is persistent or frequent—particularly if this is new for you. Unexplained weight loss, fatigue, a change in bowel habit or a pelvic mass also need clinical attention. Your GP can arrange CA 125 within the appropriate pathway and make sure follow-up happens.
A home test may provide a measurement, but it should not delay a GP appointment for ongoing symptoms. Testing is less useful when done without a plan for imaging or review. If you have a strong family history of ovarian or breast cancer, ask about genetic-risk assessment rather than relying on periodic CA 125 checks.
Seek urgent care for severe or rapidly worsening abdominal pain, fainting, heavy bleeding, vomiting with inability to keep fluids down or acute breathing difficulty. These symptoms need assessment regardless of a recent marker result.
What your results can mean
A raised result means follow-up is needed, not that cancer is present. In the NICE pathway, pelvic and abdominal ultrasound is considered next. If ultrasound is normal but symptoms continue, the clinician should consider other causes and advise when to return. Premenopausal people have a wider range of benign reasons for elevation.
A result within range reduces concern in some contexts but cannot fully exclude ovarian cancer. Persistent, changing or worsening symptoms still deserve reassessment. The date and trend may matter if a clinician repeats the measurement, but routine serial self-testing is not a substitute for evaluation.
If imaging identifies a concerning finding, specialist teams use additional information to plan care. CA 125 may also be monitored in people already receiving treatment for ovarian cancer, which is a different use from investigating new symptoms.
What to do next
If you already have a result, note the units, range, date and whether you were menstruating, pregnant or unwell. Share the complete report with your GP together with a symptom timeline. Avoid trying to explain a raised value from one benign possibility without arranging the recommended follow-up.
If the result is within range but symptoms remain, book or keep your appointment. Explain how often symptoms occur and whether they are new. A symptom diary can make persistence clearer and help your clinician decide whether ultrasound or another investigation is appropriate.
CA 125 is safest when connected to a clinical pathway. The aim is not to cause alarm, but to make sure a potentially useful marker leads to proportionate follow-up while recognising its substantial limitations.
See the CA 125 Test, read how to read a female hormone panel through your cycle, or explore women's health tests.
References
- NICE: Suspected cancer recognition and referral—ovarian cancer
- NICE: Ovarian cancer recognition and initial management
- NHS: Ovarian cancer symptoms
Sources: NICE: Suspected cancer recognition and referral—ovarian cancer; NICE: Ovarian cancer recognition and initial management; NHS: Ovarian cancer symptoms — see all references